OncoMatch/Clinical Trials/NCT04879654
Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery
Is NCT04879654 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for malignant melanoma.
Phase II, single-arm, prospective clinical study of Toripalimab(a PD-1 antibody) combined with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma after endoscopic surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: head and neck radiation
No head and neck radiation ... in the past 5 years
Cannot have received: systemic anti-tumor therapy
No ... systemic anti-tumor therapy performed in the past 5 years
Cannot have received: radioactive seed implantation
Have received radioactive seed implantation in the treatment area
Cannot have received: PD-1 monoclonal antibody
Previously received PD-1 monoclonal antibody
Cannot have received: CTLA-4 monoclonal antibody
Previously received ... CTLA-4 monoclonal antibody (or any other antibody that acts on T cell co-stimulation or checkpoint pathway)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify